| Biomarker ID | 1144 |
| PMID | 23813660 |
| Year | 2013 |
| Biomarker | HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 31 PC patients and 17 patients with benign prostatic hyperplasia were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | HPN, CLDN3, AMACR, GOLPH2, TRIB1, LOC729677, GDF15, TARP, MYC, LOC731404, ZFP36, SIM2, CTGF, GJB1, CENPN, EGR2, FBP1, KLF4, LUZP2, C8orf4, PDLIM3, CREB3L1, GCNT1, CTPS, PTP4A3 |